Clinical Trials
33 trialsCASCADE3001A
UNC Lineberger Comprehensive Cancer Center
Phase II Study of Dysplasixâ„¢ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities
Amplexd Therapeutics, Inc.
LMI-001-A-S04
National Cancer Institute (NCI)
Feasibility of HPV Self-Collection Kits for Cervical Cancer Screening
Washington University School of Medicine
KOPRETINA
The Institute of Molecular and Translational Medicine, Czech Republic
POC
Basic Health International, Inc.
(iSTAR)
Columbia University
RIFT-HPV
Institut d'Investigació Biomèdica de Bellvitge
ASHA-Health II
University of California, Irvine
Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring
The Institute of Molecular and Translational Medicine, Czech Republic
EQUIP
Qurasense
Non-Invasive Plasma Treatment for Cervical Infections: Targeting High- and Low-Risk HPV Variants
University Hospital Tuebingen
PopSci CHW4CervixHealth
Thomas Jefferson University
Pocket Colposcopy Using CARE Algorithm
Duke University
Human Papillomavirus Self-sampling for Enhancing Cervical Screening During the War in Ukraine
Karolinska Institutet
ART-CIN_IIB
Frantz Viral Therapeutics, LLC
Cervical Pre-cancer Treatment Failure Among Women Living With HIV in Zimbabwe
University of Bern
ART-VIN IIB
Frantz Viral Therapeutics, LLC
HPV
International Vaccine Institute
START-001
Marengo Therapeutics, Inc.
Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection
First Affiliated Hospital of Wenzhou Medical University
Multimodality Treatments of HPV-related Lesions of the Female Genital Tract
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
AGO-Gard
Louisiana State University Health Sciences Center in New Orleans
The Organ Transplant Recipient HPV and Skin Cancer Study
Bispebjerg Hospital
SUIVICIN
University Hospital, Bordeaux
HPV-VIM
Baylor College of Medicine
Reducing Urban Cervical Cancer Disparities
Fox Chase Cancer Center
Effect of HPV Integration on Prognosis of Young Women With CIN2 in China
Fujian Maternity and Child Health Hospital
HERSELF
Universidade do Porto
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd.
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Shanghai Bovax Biotechnology Co., Ltd.
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
Shanghai Bovax Biotechnology Co., Ltd.
Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden
Region Stockholm